Tirzepatide improves sleep apnea symptoms for adults with OSA plus obesity
Adults with moderate to severe obstructive sleep apnea and obesity had reductions in sleep apnea severity at 1 year with 10 mg or 15 mg of tirzepatide, according to topline results from two phase 3 trials. As Healio previously reported, tirzepatide (Zepbound, Eli Lilly) was approved by the FDA for chronic weight management among adults with obesity in November 2023. Topline results from the